🇺🇸 FDA
Patent

US 11633496

Muscle targeting complexes and uses thereof for treating dystrophinopathies

granted A61KA61K2039/505A61K31/713

Quick answer

US patent 11633496 (Muscle targeting complexes and uses thereof for treating dystrophinopathies) held by Dyne Therapeutics, Inc. expires Mon Apr 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Dyne Therapeutics, Inc.
Grant date
Tue Apr 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K2039/505, A61K31/713, A61K47/10, A61K47/549